A Safety Study of SGN-CD19A for B-Cell Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
Burkitt Lymphoma|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Mantle-Cell|Precursor B-cell Lymphoblastic Leukemia-Lymphoma
DRUG: SGN-CD19A
Incidence of adverse events, Through 1 month post last dose|Incidence of laboratory abnormalities, Through 1 month post last dose
Objective response according to revised response criteria for malignant lymphoma (Cheson 2007), Through up to approximately 6 week post last dose|Duration of response, Until disease progression or start of new anticancer treatment, an expected average of 6 months|Overall survival, Until death or study closure, an expected average of 1 year|Blood concentration of SGN-CD19A and metabolites, Through up to approximately 6 weeks post last dose|Incidence of antitherapeutic antibodies, Through up to approximately 6 weeks post last dose
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)